The pivotal roles of HGF/SF and MET in cancer progression and metastasis have led to considerable expectation that agents blocking HGF/SF-MET signaling could have a strong impact in the therapy of metastatic tumors and led to a major effort in the design, synthesis and development of small molecule inhibitors of the MET kinase49 as well as blocking antibodies directed against the ligand HGF/SF50, 51 and the MET extracellular region37, 52–56. The gene discussed is MET; the disease is metastatic neoplasm.